reports
Belite Bio Reports First-Quarter 2024 Financial Results and Provides C...
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Data from a 24-month Phase 2 trial in adolescent STGD1 subjects showed a sustained lower atrophic lesion growth in Tinlarebant-treated subjects compared to ProgStar participants possessing similar baseline characteristics (aged ≤18 years) (p
Moody's Ratings revises outlook on 412 US local government issuers fro...
Moody's Ratings (Moody's) has revised the outlook on 412 US local government issuers from stable to no outlook (NOO). The issuer and long-term underlying debt instrument ratings have been affirmed. RATINGS RATIONALE Please click on this link /viewresearchdoc.aspx?docid=PBM_P...
Timbercreek Financial announces Voting Results from Annual Meeting of ...
Timbercreek Financial announces Voting Results from Annual Meeting of Shareholders TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Timbercreek Financial Corp. (the "Company") (TSX:TF) announced the voting results for the election of its board of directors, which took place at the Company’s annual meeting of shareholders held on May 13, 2024 (the “Annual Meeting”). The Annual Meeting was originally scheduled to be held on May 8, 2024 but was adjourned to May 13, 2024 due to a lack of quorum. The nominees listed in the management information circular dated March 15, 2024 were elected as directors...
Moody's Ratings affirms KIPP Indianapolis, Inc. Project, IN's Ba1 reve...
Moody's Ratings (Moody's) has affirmed the Ba1 revenue bond rating on the Educational Facilities Multipurpose Revenue Bonds, Series 2020A and Series 2020B of KIPP Indianapolis, Inc. Project, IN. KIPP Indianapolis has $11 million in debt outstanding, which consists entirely of the Series 2020 bonds. ...
Aurora Spine Corporation Announces First Quarter 2024 Financial Result...
Aurora Spine Corporation Announces First Quarter 2024 Financial Results NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in spine and interventional spine technology that improves spinal surgery outcomes, today announced its financial results for first quarter ended March 31, 2024. All figures are in U.S. dollars. Financial and Business Highlights Positive EBITDAC – Q1 2024 EBITDAC was $117,171 as compar...
Moody's Ratings: No adverse rating impact on Arrow Funding Trust No. 1...
Moody's Ratings (Moody's) announced today that the addition of AUD16.7 million of mortgage loans into Arrow Funding Trust No. 1 Repo Series No. 1 on 14 May 2024 (the Substitution) would not, in and of itself and as of this point in time, result in a reduction, placement on review for possible downgr...
Infinera to Announce Preliminary Fiscal First Quarter 2024 Financial R...
Infinera to Announce Preliminary Fiscal First Quarter 2024 Financial Results on May 14, 2024 SAN JOSE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Infinera Corporation (NASDAQ: INFN) announced today that it will release its preliminary financial results for the first quarter of fiscal 2024 ended March 30, 2024, after the market closes on May 14, 2024. An investment community conference call to discuss these results and Infinera’s outlook for the second quarter of fiscal 2024 will be held the same day at 5:00 p.m. ET/2:00 p.m. PT and will be accessible live and on an archived basis as fo...
- Posmarito Pakpahan
Banking – 1Q24 Results Wrap-up: NIM Revision Due To Higher CoF
Large banks continued gaining market share and posting strong loan growth, but faced pressure in NIM due to higher CoF. Robust coverage and asset quality improvement led to a decline in CoC, except for BBRI. Optimising balance sheet, diversifying the funding and loan repricing will support NIM. The Big Four banks are trading at +0.5SD to the mean five-year forward. We recommend a strong BUY if the valuation comes close to -1SD. Maintain OVERWEIGHT.
- Hendri Effendi
- Posmarito Pakpahan
- Soomit Datta
STNE US (Neutral, TP: $20, +20%) StoneCo Q1s - Pretty solid underlying...
StoneCo reported Q1s after close. Having recently updated its accounting for membership fees (negatively affecting revenue and down through the P&L) consensus was, according to IR, a mix of old and new – and not so helpful therefore.
High Arctic to Announce 2024 First Quarter Results
High Arctic to Announce 2024 First Quarter Results CALGARY, Alberta, May 13, 2024 (GLOBE NEWSWIRE) -- High Arctic Energy Services Inc. (TSX: HWO) (“High Arctic” or the “Corporation”) intends to release its 2024 first quarter results on Wednesday, May 15, 2024 after markets close and has scheduled a conference call to begin at 11:00 am MT (1:00 pm ET) on Thursday, May 16, 2024. The filing of the 2024 first quarter results follows our announcement of May 11, 2024 for the reorganization to create two publicly traded energy services companies and return of capital to shareholders at an Annua...
Moody's Ratings affirms Alphabet's Aa2 senior unsecured rating; outloo...
Moody's Ratings (Moody's) affirmed Alphabet Inc.'s (Alphabet) Aa2 long-term issuer rating, Aa2 senior unsecured notes rating, and Prime-1 rating on the short term commercial paper program. The outlook is stable. "Despite competitive, legal and regulatory pressures, Alphabet's management team has r...
- Nicky Mapa
- Rob Carnell
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatini...
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui — Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED’s surufatinib and anti-PD-1 activity with Hengrui’s camrelizumab, promoting the immune response against tumor cells — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited...
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-...
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-306 in patients with mutated isocitrate dehydrogenase (“IDH”) 1 or 2 relapsed / refractory acute myeloid leukemia (“AML”) in China. The first patient received their first dose on May 11, 2024. ...
Moody's Ratings revises outlook on 412 US local government issuers fro...
Moody's Ratings (Moody's) has revised the outlook on 412 US local government issuers from stable to no outlook (NOO). The issuer and long-term underlying debt instrument ratings have been affirmed. RATINGS RATIONALE Please click on this link /viewresearchdoc.aspx?docid=PBM_P...
Dundee Corporation Delivers Success in Its Core Strategy, A Profitable...
Dundee Corporation Delivers Success in Its Core Strategy, A Profitable Start to 2024, and Sustained Cost Control TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Dundee Corporation (TSX: DC.A) (the “Corporation” or “Dundee”) today announced its financial results for the three months ended March 31, 2024. All currency amounts in this press release are in Canadian dollars, except as otherwise indicated. FIRST QUARTER 2024 RESULTS Reported net income from portfolio investments for the first quarter of 2024 of $12.6 million (2023 – loss of $7.5 million). The key driver of performance durin...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.